ORETICYL 25
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORETICYL 25 (ORETICYL 25).
Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule by binding to the thiazide-sensitive NaCl cotransporter, increasing excretion of sodium, chloride, and water. Deserpidine depletes catecholamines from peripheral sympathetic nerve endings by binding to the vesicular monoamine transporter, reducing vascular resistance and heart rate.
| Metabolism | Hydrochlorothiazide is not significantly metabolized; deserpidine is extensively metabolized in the liver, likely via CYP450 enzymes. |
| Excretion | Primarily renal (95% unchanged); minimal biliary (<5%). |
| Half-life | 2.5 hours; in renal impairment may extend to 8–15 hours. |
| Protein binding | ~95% bound to albumin and erythrocytes. |
| Volume of Distribution | 0.2 L/kg; confined to extracellular fluid. |
| Bioavailability | Oral: 90–100%. |
| Onset of Action | Oral: 1–2 hours; IV: 15–30 minutes. |
| Duration of Action | 6–12 hours; antihypertensive effect may persist 24 hours after single dose. |
Hydrochlorothiazide 25 mg orally once daily; may increase to 50 mg daily if needed.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: no adjustment; GFR <30 mL/min: not recommended (thiazides ineffective). |
| Liver impairment | Child-Pugh A/B: use with caution; Child-Pugh C: contraindicated due to risk of electrolyte disturbances and hepatic encephalopathy. |
| Pediatric use | 0.5-2 mg/kg orally once daily; maximum 50 mg/day. |
| Geriatric use | Start at 12.5 mg orally once daily; increase slowly due to increased risk of electrolyte imbalance and hypotension. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ORETICYL 25 (ORETICYL 25).
| Breastfeeding | Hydrochlorothiazide (HCZ) is excreted into breast milk in low concentrations; M/P ratio approximately 0.2-0.5. Clinical effects in nursing infants are unlikely but may include diuresis and electrolyte disturbances. Consider alternative agents with more established safety profiles, especially in neonates or preterm infants. |
| Teratogenic Risk | Pregnancy Category C. First trimester: Limited data; potential risk based on diuretic-induced maternal hypovolemia and decreased placental perfusion. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and neonatal adverse effects (hypoglycemia, electrolyte disturbances) due to maternal electrolyte imbalance and volume depletion. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to hydrochlorothiazide, deserpidine, or sulfonamide-derived drugs","History of depression, especially with suicidal tendencies","Active peptic ulcer","Electroshock therapy","Pheochromocytoma"]
| Precautions | ["May cause hypokalemia, hyperuricemia, and hyperglycemia","Deserpidine may cause mental depression, peptic ulcer, and Parkinson-like symptoms","May increase risk of non-melanoma skin cancer","Electrolyte monitoring recommended"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, serum electrolytes (Na, K, Cl, bicarbonate), renal function (BUN, creatinine), and uric acid. Assess fetal growth and amniotic fluid volume via serial ultrasound. Monitor neonatal for electrolyte imbalances and hypoglycemia after delivery. |
| Fertility Effects | No direct evidence of adverse effects on fertility. However, diuretic-induced electrolyte disturbances or volume depletion may theoretically impact ovulation and implantation. No specific human data available. |